Ultragenyx Pharmaceutical Inc (RARE) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Ultragenyx Pharmaceutical Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Ultragenyx Pharmaceutical Inc's ROI in the second quarter of 2026?
Ultragenyx Pharmaceutical Inc recorded a cumulative net loss of $-586 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -56.99%.
Within the Healthcare sector 298 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2090 to 3460.
In a significant stride for patients with rare bone disorders, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a company committed to innovating treatments for rare and ultra-rare diseases, has proudly announced that it has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for its investigational drug, setrusumab (UX143). This therapy targets the reduction of fracture risk in patients suffering from osteogenesis imperfecta (OI) Types I, III, or IV, specifically in individuals aged two years and older. The FDA s designation underscores the potential of setrusumab to provide a meaningful therapeutic advancement for patients who face the daily challenges posed by this brittle bone disorder, which is characterized by fragile bones and an increased susceptibility to fractures.Setrusumab s designation as a Breakthrough Therapy reflects the recognition of the urgent medical need for effective treatments in the field of osteogenesis imperfecta. OI affects children and adults alike, presenting significant health burdens and disrupting normal activities of life. By targeting the genetic and molecular basis of OI, setrusumab aims to not only decrease the frequency of fractures but also to enhance the overall quality of life for patients and their families.
On September 3, 2024, OKX Explorer, a prominent blockchain search engine and analytics platform, announced the integration of support for Bitlayer, a platform designed for the management and analysis of blockchain data. This new addition aims to bolster the capabilities of OKX Explorer, allowing users to leverage advanced tools for navigating and understanding the complexities of blockchain networks.OKX Explorer is widely recognized for its user-friendly interface and robust functionality, offering a comprehensive suite of tools for both casual users and industry professionals. The platform provides real-time data, transaction tracking, and blockchain analytics, making it an essential resource for stakeholders in the evolving landscape of decentralized finance and Web3 applications.
Ultragenyx Welcomes New Talent with Stock Incentives: A Strategic Move in the Biopharmaceutical SectorIn a significant move to enhance its workforce, Ultragenyx Pharmaceutical Inc. a leading biopharmaceutical company dedicated to developing novel therapies for rare and ultrarare diseases, has announced the grant of 37,975 restricted stock units (RSUs) to 12 newly hired non-executive officers. This strategic inducement aligns with the company s goals of fostering innovation and ensuring that it remains competitive in the challenging field of rare disease treatment. The grant, approved by the compensation committee of Ultragenyx’s board of directors, reflects a commitment to attracting top talent essential for advancing the company’s mission. Details of the Inducement Grant On August 21, 2024, Ultragenyx disclosed the inducement grant under Nasdaq Listing Rule 5635(c)(4). This rule permits companies to grant equity awards to new employees as an incentive for their contributions from the onset of their employment. The RSUs were granted as part of the Ultragenyx Employment Inducement Plan, which is designed to incentivize incoming personnel, thereby motivating them to contribute to the company’s vision and strategy from the very beginning.
In a groundbreaking development, Ultragenyx Pharmaceutical Inc has recently announced its plans to file for accelerated approval of UX111 for the treatment of Sanfilippo Syndrome Type A (MPS IIIA). This announcement comes as the company reached an agreement with the FDA regarding the use of cerebral spinal fluid (CSF) heparan sulfate (HS) as a surrogate marker for accelerated approval. These milestones carry significant implications for the company s future and the patients affected by this devastating disease. Expansion into Sanfilippo Syndrome Treatment: Sanfilippo Syndrome, also known as MPS IIIA, is a rare and severe genetic disorder that primarily affects the brain and nervous system of children. There is currently no approved treatment for this condition, leaving families with limited options. Ultragenyx s decision to file for accelerated approval of UX111 demonstrates their commitment to addressing unmet medical needs in the rare disease space.
Financial Statements
Ultragenyx Pharmaceutical Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
